Baroness Meacher: access to medical cannabis in the UK

Baroness Meacher is the chair of the All-Party Parliamentary Group for Drug Policy Reform and has a long history in social work and mental healthcare within vulnerable communities.

Medical Cannabis Network speaks with Baroness Molly Meacher to discuss her support for access to medical cannabis and her campaigning on what is an increasingly contentious issue in the UK.

She is active in campaigning for widespread drug reform and regularly engages in debates on the subject of medical cannabis given her experience in helping people who were using it therapeutically.

MCN sat down with Meacher to discuss how she came to be aware of the remedial properties of the plant, cases of particular note she has been involved in, and how she is working to raise awareness and improve access to medical cannabis for British patients.

Your background in social work and mental healthcare led you to discover that cannabis has therapeutic benefits, what kind of conditions and symptoms did you find that people were often using it to treat?

When I asked patients why they were using cannabis when already suffering with a psychotic illness (I was convinced that it must surely be interacting with their pharmaceutical medication) they would reply: ‘It makes me feel human, and even if I experience more hallucinations it is well worth it because I feel alive.’

It was obvious to me that cannabis was very helpful in combating some of the negative symptoms of psychotic illness such as lack of libido, lack of feeling and lack of motivation; clearly cannabis was improving all of this. It is wonderful that people are now doing the research into the use of CBD as an antipsychotic medication. It’s very interesting.


In your opinion, to what extent is cannabis being used to address a previously unmet clinical need within vulnerable populations?

Cannabis is frankly perfect for the treatment of psychosis and its negative symptoms. The use of CBD is the priority, and that is where research is now focusing. I personally feel that perhaps certain people with psychosis could manage without many of the powerful antipsychotic medications they are being prescribed if they had access to CBD in addition to psychotherapy to help them to manage and deal with the symptoms.

If they were less anxious about the medications and responding negatively to them, then they may improve slightly anyway. I think it is a very interesting area of research.

In terms of mental illness in a broader sense, I know that people use cannabis to help them with depression and anxiety; I’m not an expert in those areas but there are so many people who find it valuable. Again, some robust research would be very helpful in those areas. In the meantime, it is my view that if patients are reporting that they feel better using medical cannabis products then NICE and the other regulatory bodies need to find ways of approving cannabis for people who are very vulnerable from depression and anxiety while better research is being done, because it clearly doesn’t appear to be doing adults any harm.

Are there any particular cases of note you can recall in which someone experienced substantial improvement or benefit as a result of using medical cannabis, or a particular incident which convinced you of its efficacy?

I have met so many people who were suffering terribly and whose lives have been completely transformed by cannabis. For example, Lara Smith comes to mind. She has major spinal conditions and was put on 34 different medications which did very little to alleviate her pain but caused unbearable side effects.

She decided to stop taking those and now exclusively uses cannabis, which alleviates her pain more effectively than anything else. I also met somebody on a television programme who suffers with Crohn’s disease; he was told he would die within six years and now 10 years on he simply takes cannabis and he’s absolutely fine.

Somebody very close to me suffers from PTSD and since using cannabis he has reported that it has helped him massively.

You have discussed how the need for research into how access to medical cannabis could reduce the burden on the NHS. What would need to happen in order for this research to be commissioned and how would it work? Do you think this is something that public and medical professionals would quickly support?

I think there would be a huge amount of support as research findings come out ever more strongly in relation to medical cannabis’ impact on all of the different conditions.

For example, Drug Science led by Professor David Nutt is going to make medical cannabis available to 20,000 people as a pilot scheme, in the course of which they will be looking at measuring the outcomes, the cost, the positive effects on symptoms, and so on. They are going to have a meeting with NICE to make sure that they will actually take the findings of this research very seriously.

I understand that NICE are also finally considering moving away from a requirement for research to be in the form of randomised controlled trials (RCTs), which of course are not helpful for cannabis in many ways. In my opinion, we simply need other forms of research. Drug Science are leading the way in this country in terms of breaking away from RCTs and using outcome measures and so on.

This, of course, has been done a lot in the USA and although NICE looked at more than 19,000 different research studies, they dismissed all but four of them because they were not RCTs. There really is enough research out there for a great deal of liberalisation in prescribing cannabis and this research is still ongoing, which is wonderful.

Do you feel that it will present a significant challenge if medical cannabis products have to be treated in the same way as other pharmaceuticals, which are typically very expensive and take a long time to reach the market?

I think it would be a disaster, quite frankly, if this country holds on to the requirement for RCTs. What is interesting is that the Queen’s speech includes The Medicines and Medical Devices Bill. This will change the requirement for such costly research studies in order to get new medicines into the market more quickly.

Even if this is only for a short period of time while more work is done, I think it is a potentially very exciting piece of legislation.

There is a burgeoning realisation that we are just too tough here. It is significant that 50 countries have approved medical cannabis and most of them have got thousands of patients being prescribed it, rather than merely tens; we are way behind.

Even though access to medical cannabis is technically possible in the UK, there is criticism surrounding the number of prescriptions issued and that they have been issued privately at a cost. What in your opinion are the largest barriers patients are facing in trying to access to medical cannabis, and how can this be addressed?

Medical resistance is huge. Many doctors were educated and trained at a time when cannabis was regarded as a dangerous and illegal drug. So, first and foremost their mindset needs to change. Even if that happens, they are being inhibited from prescribing cannabis-based medicines anyway and they are expected to take full risk and responsibility. They feel that this is a big problem because cannabis is in the ‘specials’ category and not just a standard medication they would usually prescribe.

The next problem is that only specialised consultants can issue medical cannabis prescriptions, and all of the forms and procedures this entails are incredibly time consuming and onerous; they simply don’t have the time to be doing this.

There are many barriers at the medical level, and then there are barriers in terms of securing licences for producers. We don’t yet have readily available licensed production of the medicines here, there is the rule that only one month’s supply can be imported at a time on a named patient basis, which is ridiculous and only serves to ensure that the cost is huge.

There are medical barriers, there are rule-related barriers, and of course the bureaucracy and extortionate cost. These are the things that have to change and change quickly to give patients access to medical cannabis.

How would you argue these issues should be addressed to improve access to medical cannabis?

There is already important work going on and there are wonderful people such as Professor Mike Barnes who has set up clinics and is also training other doctors. There are organisations like Drug Science who are doing wonderful work as well, so there are already developments on the medical side.

I am going to have a meeting with officials about all the rules and bureaucracy and to discuss what the government can do to free up the availability of medical cannabis. NICE had a meeting with me yesterday, they need to move and I’m sure they will; how quickly that will happen remains to be seen, but it will be as quickly as they possibly can.
NICE need to move to recognise medical cannabis in a more positive way and to provide guidance that will actually encourage doctors to prescribe.


Baroness Molly Meacher
All Party Parliamentary Group for Drug Policy Reform

Gavin and Stacey slammed for ‘pushing message cannabis is OK’ as Pam and Mick light up in the living room

Gavin and Stacey has been hit with more backlash, but this time critics are concerned viewers casually will turn to cannabis because Mick (played by Larry Lamb) and Pam (Alison Steadman) smoked a spliff with pals Dawn (Julia Davis) and Pete (Adrian Scarborough).


During the Christmas Special – which celebrated homophobic slur f****t for reasons which are yet to be made clear by the BBC or creators James Corden and Ruth Jones – Dawn broke up with Pete for the millionth time because, in her words, he was a ‘junkie’.


Turns out she found a joint in his car and lost it with her husband until Pam and Mick assured they used to chase the dragon on the daily before Gavin was born. Moments later said spliff was ablaze and the foursome had a whale of a time in the living room.


In what was arguably otherwise a pretty dry 60 minutes, the lifelong friends mischievously breaking taboo for a giggle was by far the highlight of the long-awaited return of BBC One’s divisive comedy.

However, some have slammed the BBC for pushing what could be a dangerous narrative, ignoring the underlying dangers of smoking marijuana.

Lord Nicholas Manson lost his son to drugs, and revealed he saw the crippling effects of cannabis first hand, accusing Gavin and Stacey of ‘pushing a strong subliminal message that cannabis is perfectly OK and those who fear it might be otherwise are fair game for mockery?’


He told the Daily Mail: ‘Our tragedy is not unique. Super-strong cannabis is mentally damaging, it is thought, for about one in nine regular users. Because of developing brain issues before the age of 25, the young are even more susceptible to its injurious effects.’

Mary Brett, of campaign group Cannabis Skunk Sense, added: ‘It is very disheartening and actually frightening when television people think it’s funny to smoke cannabis.’

The BBC declined to comment on this story.

Gavin and Stacey returned to record ratings, with 12 million viewers tuning in on Christmas Day while millions more will have caught up on iPlayer.

Naturally, then, audiences have been calling for a fourth series in their droves after that headache of a cliff-hanger, while the cast has been told there could be more episodes on the horizon.

Why Canada’s cannabis bubble burst

More than a year ago, Canada made recreational cannabis legal. So why are people still buying it on the black market?

When Canada legalised marijuana just over a year ago, it seemed like anyone who was anyone wanted to break into the market.

The media nicknamed the frenzy Canada’s “green rush”, as investors like Snoop Dogg and the former head of Toronto’s police force clamoured to get a slice of the multi-billion-dollar-pie.

But like the gold rush of the 1850s, the lustre would soon fade, leaving prospectors in the dust.


“It didn’t take a rocket scientist to recognise that these stocks were trading on fantasy and not on fundamentals,” says Jonathan Rubin, CEO of New Leaf Data Services.

With decades of experience in the energy commodities markets, Mr Rubin saw the legalisation of cannabis in states like Colorado and California in the US (and later Canada) as a “once in a lifetime” opportunity to get in on the ground floor of a brand-new commodity.


“I had this epiphany that this is going to be a commodity just like any other commodity,” he told the BBC.


What that meant was that like the price of wheat or pork, the wholesale price of cannabis was going to fluctuate with the market. So instead of investing in the cannabis itself, Mr Rubin started New Leaf to track the price of cannabis in states where it was legal. Investors and others in the industry pay for access to this data.



This business model has given Mr Rubin an interesting vantage point of how the market has unfolded.

In Canada, he says, the rollout has been disappointing.


“They haven’t had the growth in sales and earnings that they’ve envisioned,” he said. “I don’t want to say it’s a failure, but there’s definitely frustrations.”

Wholesale prices have dropped by about 17% since New Leaf started tracking data, which has kept profit margins tight for producers.

Sales have also slowed, according to Statistics Canada.


It’s led to a rollercoaster ride for the stock prices of publicly traded cannabis companies.


In May 2018, Canadian producer Canopy Growth made headlines when it became the first marijuana company to list on the New York Stock Exchange.

Six months later, the stock price about doubled when it hit a high of $52.03 (£39.77) a share.

Now, the stock price is back to where it was, and their competitors have suffered similarly drastic losses.

Growing pains

There were early signs of trouble.

When cannabis became legal on 17 October 2018, there wasn’t enough supply to meet the demand.

Long lines and backlogs of online orders plagued consumers. Producers weren’t sure what strains would be most popular where, and kinks in the distribution chain were still being ironed out.


“Trying to understand what strains we should grow, in what formats and what quantities – we did a great job but we didn’t nail everything,” says Canopy president Rade Kovacevic.

A patchwork of provincial laws have also made it harder to get products to consumers. While it’s easy to buy cannabis in some places, in others brick-and-mortar shops are few and far between.

This is especially true in Ontario, Canada’s most populous province. Red tape and a cap on the number of cannabis retail outlets have made rollout slow. Retail licenses were awarded by lottery, and the province held the number of licenses at 24, to serve a population of 14.5m.


Where there was once a shortage, now producers have too much product, in part because of the lack of retail.

In September, Canadians bought 11,707 kilograms (25,809 lbs) of dried cannabis flower in Canada. But producers had a total of about 165,000 kilograms of finished and unfinished products ready for sale, or more than enough to meet the demand for an entire year.

Mr Kovacevic blames the lack of retail in Ontario for a lot of his company’s woes.

“I think that lack of continuity of points of purchase across the country slowed the transition from the black market to the legal market,” he said. “It was a challenge.”

Black market still thriving

When the government announced its decision to legalise cannabis, one of its principal reasons was to reduce the black market.



But Statistics Canada estimates that about 75% of cannabis users still use illegal cannabis.

“There’s a very strong resistance to the legal stores in the sense that a) it’s more expensive and b) there aren’t enough of them. They’re not close to them, so they just deal with their local guy like they always have,” says Robin Ellis, co-founder of Toronto retailer The Friendly Stranger and a long-time activist for cannabis legalisation.


There were only five retail stores open in Toronto in 2019, and they were all concentrated in the downtown, which meant many people had to drive miles if they wanted to buy legal pot.

Legal cannabis is also far more expensive.

The retail price of legal cannabis has gone up, from C$9.82 ($7.49, £5.73) a gram in October 2018 to C$10.65 a gram in July, according to Statistics Canada.

Meanwhile, the illegal price has dropped from C$6.51 to C$5.93.

The case for cannabis

Perhaps one of the reasons why sales have been lacklustre for producers is that, contrary to some health experts’ fears, legalising marijuana didn’t turn everyone into a pothead.

Over the past year, the percentage of Canadians who used cannabis grew from 14% to about 17%.


Use varies a lot by age, with people between 25-34 being the most likely to use cannabis, followed by those ages 15-24 (the legal age to use cannabis varies in Canada from 18-21). Older people are the least likely to have used cannabis, – but use has accelerated much faster for them than for other age groups, and seniors are the most likely to buy only legal weed, according to Statistics Canada.

This is in line with research in the US that shows that in states where cannabis has been legalised, usage among teenagers has actually decreased or stayed the same.


Mr Ellis, a long-time cannabis activist, says it’s important to remember that despite the industry’s growing pains, legalisation has been largely a success.

“I don’t think Canadians fully understand the magnitude of this change. We didn’t just make something quickly available – it took 25 years of hard work to get legalisation ,” he says.

Legalising marijuana has also opened up a whole new industry for the Canadian economy.

Sales of legal dried bud blossomed from about 4,405 kilograms in October 2018 to 11,707 kilograms in September 2019.

The pot industry is now worth C$8.6bn, or about .3% of the country’s GDP in 2018.

Turning over a new leaf

Things are looking brighter for the New Year, people in the industry say.

In December, the Ontario government announced that after a slow and fitful start, the province will open itself up to more cannabis retail. It will do away with the lottery system, the cap on the number of private stores and cancel some pre-qualification requirements.

It’s welcome news to people who’ve been trying to get into the market.

“We’re really looking forward,” Mr Ellis says. His store, the Friendly Stranger, sells cannabis accessories, and he intends to open as many as 20 licensed retailers in the new year.

Producers will also be allowed to open up one storefront on site, similar to how some breweries can sell beer direct to consumers.

“If everything goes smoothly and they follow up, hopefully we’ll see more of an equilibrium in terms of supply-demand balance,” Mr Rubin says.


More kinds of products will also be coming to the market soon. The government is legalising alternative cannabis products, like edibles and vapes. Those products are expected to hit shelves around Christmas.

Up until now, Health Canada has only permitted cannabis oil, dried flowers, seeds and plants to be sold to consumers.


Mr Rubin expects these new products to help retail sales grow by 30-40%. The formats are expected to be a hit, especially amongst people who’ve never tried cannabis before.



“There’s going to be a lot of people out there who are going to want to try cannabis for the first time in a format that’s not smoking or vaping,” says Mr Ellis.

The new product lines are helping some producers attract investment. Constellation Brands, which makes Corona beer, owns a 38% stake in Canopy.


Mr Kovacevic, Canopy’s president, says they will rollout THC-laced beverages by early 2020. These products are designed to have a precisely known, low-level dose of THC, which would produce a buzz equivalent to the effect of one beer. They will not contain alcohol.


The company will also start making THC-laced chocolates.


“I think it’s a great opportunity,” he says. “If you look at products like vapes and edibles, those are products that are ubiquitous in the black market, and Canadians will now have the opportunity to go to a legal store.”

Coca-Cola Says It Doesn’t Have Plans to Enter Cannabis Market

Coca-Cola Co. is dousing speculation that it’s getting into the cannabis business.


Speculation surged after a video posted to YouTube — since deleted — by a user with the screen name “Gabor the Blind Guy” showed a Coca-Cola can with a childproof lid. The man in the video says that his father is a head engineer for a company that “produces bottling and capping machines for many major pharmaceutical and food companies.”


He then says that Coca-Cola is planning on debuting a new line of its classic drink in Canada that will feature CBD extract, the non-psychoactive ingredient in marijuana that treats pain but doesn’t get you high.


“These rumors are untrue,“ Coca-Cola said in an emailed statement to Bloomberg News. “As we have stated many times, we have no plans to enter the CBD market.”


A saved copy of the video was posted on Reddit Inc.’s WallStreetBets forum.


Coca-Cola said in 2018 that it was looking at the cannabis drinks market. The news fueled stock gains for companies like Aurora Cannabis Inc. The Atlanta-based soft drinks maker was in talks with Canadian marijuana producer Aurora Cannabis to develop the beverages, according to a report at the time from BNN Bloomberg Television.


Aurora did not respond to inquiries from Bloomberg News on Thursday about a possible partnership with Coca-Cola.

This is what to do if you think your neighbours are smoking cannabis

People smoking cannabis in their own homes continues to cause problems in some communities.

This can create a problem for neighbours who have to put up with the notoriously punch stench wafting towards them.

While some people may not be too bothered about what people get up to in their own homes, others will find the smell in particular annoying.

The smell of cannabis is quite hard to miss or mistake and it’s even harder to get rid of.


But what can you do, if anything, if you think your neighbours are smoking or even growing the drug near your home?


Although some people think that it’s perfectly legal if you’re only smoking cannabis in your own home then you’re sadly mistaken.

Cannabis is still a Class B drug and anyone caught in possession is committing an offence and will be dealt with by police.

South Yorkshire Police said the force and its partners ‘will continue to take action to improve the quality of life for communities who are affected’.

However, they have stressed that their best method of tackling the problem is by help from the public.


A police spokesperson said: “Local residents are often best placed to see on a daily basis whether their neighbours are behaving suspiciously and could be in possession of, cultivating or supplying drugs in their homes.”

But, police have also stressed that your neighbours won’t find out that you’re the one who’s tipped them off.

Officers will say they received a call about cannabis usage and may also use the tip-off as a starting point on areas they will patrol. If the officers then smell the cannabis themselves, they may knock on the door and tackle the problem themselves.

Crimestoppers have also said that people can contact them anonymously if they think their neighbours are smoking or cultivating cannabis near them. A spokesperson said: “If you spot any of the signs that there may be a cannabis farm in your community you can call Crimestoppers anonymously on 0800 555 111 or use our Anonymous Online Form.


“You will not be asked any personal details and neither your telephone number nor IP address will not be traced or recorded.” However, if your neighbours rent their property, you can contact their landlord about this but are constraints as to what they can do.

A spokesperson for Nottinghamshire Police said: “If you own or let a property you need to be aware of your responsibility to ensure cannabis is not grown on your premises.

“Consequences of allowing cannabis cultivation include reduction in property values, increased insurance premiums, hostile tenants, and up to 14 years imprisonment and a criminal record.”

If a landlord suspects the use of cannabis on their property, they can arrange a visit as long as they have warned their tenant they will be doing so. However, landlords are not bound to keep your tip-off anonymous like the police will do.

Italy court rules home-growing cannabis is legal, reigniting dispute

ROME (Reuters) – Italy’s Supreme Court has ruled that small-scale domestic cultivation of cannabis is legal, in a landmark decision triggering calls for further legalisation from weed advocates and anger from the country’s conservatives.


Called on to clarify previous conflicting interpretations of the law, the Court of Cassation decreed that the crime of growing narcotic drugs should exclude “small amounts grown domestically for the exclusive use of the grower”.

The ruling was made on Dec. 19, but went unnoticed until Thursday, when it was reported by domestic news agencies and immediately fuelled a simmering political debate over cannabis use in Italy.

“The court has opened the way, now it’s up to us,” said Matteo Mantero, a senator from the co-ruling 5-Star Movement.


Mantero presented an amendment to the 2020 budget calling for legalisation and regulation of domestic cannabis use, but it was ruled inadmissible by the senate speaker from Silvio Berlusconi’s conservative Forza Italia party.

“Drugs cause harm, forget about growing them or buying them in shops,” Matteo Salvini, leader of the right-wing League Party said in a statement on Friday, in reference to shops selling low-strength “legal weed” that are widespread in Italy.

Maurizio Gasparri, a senator from Forza Italia which is allied to the League, said the first law the centre-right coalition would approve if it came to power “will cancel the absurd verdict of the court”.

Salvini, who was interior minister until he quit the government in August in a failed bid to trigger elections, pushed for the closure of legal weed shops and cheered in May when the Supreme Court said many of their products should be banned.


The commerce has thrived in the last three years in Italy under 2016 legislation allowing cannabis with a psychotropic active ingredient (THC) level below 0.6 percent.

While the anti-establishment 5-Star Movement favours a more liberal approach to cannabis, its centre-left and centrist coalition allies are more cautious, meaning future legislation on the issue remains in doubt.


Taxpayers have spent more than £2.5 billion detaining up to 8,000 people a year for cannabis offences since 2015.


Lots of facts and figures on the costs and waste of cannabis prohibition to the UK, obvious me thinks. :g:


Listening to the Matt Stadlen (idiot presenter), LBC phone in now, some real cretins going on about the mental health dangers. :thumbdown:

More from David Lammy earlier, he’s pro regulation, but wants to make it mild and has same ‘risk to mental health’ slant. :bag:

Let the profits convince them, that the only language they understand. 




Cannabis-based drug for epilepsy to be fast-tracked into NHS

Cannabis-based drug for epilepsy to be fast-tracked into NHS

Epidiolex will be available from 6 January after NHS deal with manufacturer

Sarah Boseley Health editor

Sat 21 Dec 2019 01.00 EST

Cannabis-based medicine is to be fast-tracked into the NHS, allowing thousands of people to be prescribed the drugs, including children with severe epilepsy.

Last month the NHS struck a deal with the manufacturer GW Pharmaceuticals to bring down the price of Epidiolex, which has been approved by the European medicines agency for use in children over the age of two who suffer from seizures associated with two rare and severe forms of epilepsy – Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

NHS England has said it will speed the process through so that the drugs will be obtainable through doctors from 6 January.

Clinical trials have shown the treatment could reduce the number of seizures by up to 40% in some children when used in combination with another drug, Clobazam. It is estimated that 2,000 people a year could benefit.

The move will not end the calls for cannabis-based medicines to be made easily available on the NHS for people with other conditions. Sativex, GW’s cannabis-based medicine for multiple sclerosis, has been rejected because of its high price, to the dismay of patients and campaigners. Others have unsuccessfully campaigned for approval of cannabis medicines to relieve pain.

This year NHS England published a review of when it is safe and appropriate to consider prescribing unlicensed cannabis-based medicines. But it has become apparent that doctors are unwilling to take the responsibility without more evidence on the effects and safety.

The new twice-daily drug is licensed in both the US and Europe. It contains plant-derived, strawberry-flavoured cannabidiol but not THC, which is responsible for the high from smoked cannabis.

“The NHS is committed, through the Long Term Plan, to improving the lives of all those affected by rare diseases,” said Simon Stevens, the NHS England chief executive. “Living with or caring for someone with severe epilepsy is exceptionally challenging, especially as there are so few treatments available for the rare forms of the condition. Thousands of people including children will now have access to this treatment, which has the potential to make a real difference.”



Teenager tried to flee from police with £600 of cannabis in jacket



My last post i have to get back to the UK then do family stuff then have Christmas, so thank you for looking at the news and thanks for all your likes and have a great Christmas and a wonder new year and i will see you sometime in the new year and be safe :yep:


 A WOULD-BE teenage drug supplier tried to flee from police in a Greenock street with £600 worth of cannabis in his jacket.

William McPhee, 19, bolted from the front passenger seat of a car at traffic lights as he saw officers closing in on him.

He was quickly chased down and four knotted plastic bags containing the drug were recovered from him in Baker Street.

McPhee has pleaded guilty at the sheriff court to being in possession of cannabis with intent to supply.


But he has been spared a custodial sentence after the court heard how the cannabis was only to be shared among his friends.

Defence lawyer Aidan Gallagher said: “It was not possession on a commercial basis.”

The court heard how McPhee was in the car with a friend at around 4.35pm on June 28 when police spotted the vehicle.

Prosecutor Lindy Scaife said: “Officers had intelligence regarding the vehicle and drugs.


“As the police vehicle turned and made its way towards the car the accused opened the door and ran in the direction of Baker Street.

“There were 160 grams of cannabis in total, with a street value of approximately £600.”

Solicitor Mr Gallagher said: “In the lead up to the offence he was smoking a substantial amount of cannabis and his use of it increased following a bereavement.

“Since the date of this offence he describes it as a watershed moment and he has curbed his use of cannabis since.

“He has the prospect of an apprenticeship with a local renovation firm, and I put it no higher than that.”

Sheriff Andrew McIntyre told McPhee: “Having possession for social supply is nonetheless serious in my view, particularly here in Greenock where there is a serious problem with the use of controlled drugs.


“In your case I take account of all the circumstances and there is an alternative to custody here.”

McPhee, of Tasker Street, was placed under supervision for nine months and he will be on an electronic tag to remain within his home between 8pm and 7am each day for five months.

Christmas hip hop – Dance – Jingle Bells By Dreams House Dance Academy  2019 



Bongme :yinyang:

Your message has been successfully sent.
Oops! Something went wrong.

Get in touch

If you wish to enquire about anything, or just say hi, please fill in the form opposite, or email us on:

Copyright 2020